GSK-209762/136 (MeMuRu-136)

A phase III, blinded, randomized, multicenter U.S. study evaluating the clinical consistency of three production lots of SmithKline Beecham Biologicals' MMR vaccine (PRIORIX) and comparability of PRIORIX with Merck's M-M-R IIvaccine, administered to healthy children 12 to 18 months of age
Measles, Mumps, Rubella Vaccine
209762/136 (MeMuRu-136)
Measles; Mumps; Rubella
Phase 3
An annotated case report form is not available for this study. A blank case report form will be provided. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
June 2015